Exicure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Exicure, Inc. on November 6, 2017, reporting events occurring on November 2, 2017. The filing details a "Subsequent Closing" of a private placement financing previously initiated in October 2017.
Key Financial Metrics
- Gross Proceeds (Subsequent Closing): Approximately $5.6 million from the sale of 1,858,501 shares of common stock.
- Total Private Placement Proceeds: Approximately $31.5 million raised across all closings to date.
- Share Price: $3.00 per share.
- Placement Agent Fees: $1.9 million in cash fees received to date.
- Placement Agent Compensation (Equity): Warrants to purchase 413,320 shares at $3.00 per share and 50,000 shares of common stock.
- Reimbursed Expenses: Up to $50,000 paid to placement agents.
Material Changes
The primary material change is the completion of the second additional closing of the private placement, increasing the total capital raised to approximately $31.5 million. The company noted that the period for additional closings may be extended by the placement agents up to November 30, 2017. If over-subscribed, the company may sell an additional 3,333,333 shares.
Outlook, Risks, and Management Commentary
The filing includes a cautionary note regarding forward-looking statements concerning the use of proceeds, technology, and clinical objectives. The company states that actual results could differ materially from these statements. Risks are referenced in the "Risk Factors" section of the Initial Closing 8-K filed on October 2, 2017. The sale of shares was conducted on a "reasonable best efforts" basis and exempt from registration under Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the total number of shares outstanding post-closing and the dilution impact of the 1,858,501 new shares plus placement agent warrants and stock.
- Confirm the status of the potential extension of the private placement through November 30, 2017, and the likelihood of the additional 3,333,333 over-subscription shares being issued.
- Review the "Risk Factors" in the October 2, 2017 Initial Closing 8-K for specific clinical and regulatory risks.
- Examine the Registration Rights Agreement (Exhibit 4.2) to understand future liquidity implications for investors.